Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
NextPlat Corp (NXPL)
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-11-04
$7.59-5.71%
Close 2026-11-05 · 1-day change
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.61 → 0.61 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for NXPL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Positive operating income by Q3 2026 | A primary condition in NextPlat Corp's published investment case. The stated target is >0% operating income. | Improving | operating income remains negative through Q3 2026 | Operating income: $-127,000 FY2026-Q2; GAAP. Published target: >0% operating income. Target and observation units differ. Aug 13, 2026-127,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making growth and execution story, not yet a proven durable compounder. The thesis is in watch territory: management has made progress toward positive operating income, while recent financial performance remains below its industry cohort.
The valuation model describes NXPL as cheap versus peers, but confidence in that view is low. The expectations gap is negative, while the peer comparison also shows a modest premium, so the valuation evidence is mixed rather than a clear sign that expectations are undemanding.
Near term, the main test is whether operating progress continues: the operating loss narrowed from $1.1 million in the first quarter of 2026 to $127,000 in the second, and gross margin rose from 35% to 40%. Contracted pharmacy revenue grew 136% year over year in the second quarter, but the business remains loss-making and its risk label recently rose to high; a guidance cut would be a meaningful setback.
The multi-year thesis depends on reaching positive operating income in the second half of 2026 and continuing to expand higher-margin contracted services. Acquisition execution is another swing factor, while easier interest rates and stabilization among large technology companies could support the sector backdrop but would not replace company-level progress.
Over the next one to three years, NXPL’s case is improving execution against a still-loss-making, high-risk base, with contracted services growth offering evidence of progress. The thesis remains watchful because sustained operating improvement and successful growth are not yet established. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 3 supplied quarters. Management reported: “Management continues to expect that the addition of higher-margin contracted healthcare services revenue supported by the Company’s more efficient expense structure will contribute to sustainable positive operating income for the remainder of 2026.” “Management expects that the addition of higher margin contracted healthcare services revenue combined with reduced levels of operating expenses throughout 2026 will enable the Company to achieve positive operating income in the latter half of 2026.” Operating income was $-0.127 million in 2026-Q2.
Grow higher margin healthcare services revenue | The company wants more revenue from higher margin healthcare services. | Improving | healthcare services revenue does not grow next year | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “Contracted pharmacy revenue increased 136% to approximately $2.2 million, compared with approximately $0.9 million in the prior-year period.” “First quarter 2026 Healthcare Operations pharmacy contract revenue increased to approximately $1.9 million from approximately $1.4 million in the prior year period.” Delivery assessment Nov 4, 2026 |
Reduce operating expenses in 2026 | A primary condition in NextPlat Corp's published investment case. The stated target is operating expenses decline in 2026. | Intact | operating expenses do not decline in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “Excluding a one-time increase in professional fees, overall operating expenses declined approximately 8% due to the Company’s ongoing refocusing and streamlining efforts.” “● Total operating expenses for the quarter ended March 31, 2026, decreased to approximately $4.5 million from approximately $4.9 million in the prior year quarter, a reduction of approximately $0.4 million, or 9%.” Delivery assessment Nov 4, 2026 |
Revenue growth to $72M in 2027 | A supporting condition in NextPlat Corp's published investment case. The stated target is revenue >= $72 million. | Intact | revenue estimate falls below $48 million in 2026 or $72 million in 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “Contracted pharmacy revenue increased 136% to approximately $2.2 million, compared with approximately $0.9 million in the prior-year period.” “First quarter 2026 Healthcare Operations pharmacy contract revenue increased to approximately $1.9 million from approximately $1.4 million in the prior year period.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.58 → $0.61 · observed estimates
$0.07B → $0.07B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-07-25 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-07-26 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-07-27 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-07-28 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-07-29 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-07-30 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-07-31 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-01 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-02 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-03 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-04 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-05 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-06 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-07 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-08 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-09 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-10 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-12 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-13 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-14 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-15 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-16 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-17 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-18 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-19 | $0.58 | $73,000,000 | 1 / 1 |
| 2026-08-20 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-21 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-22 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-23 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-24 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-25 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-26 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-27 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-28 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-29 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-30 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-08-31 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-01 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-02 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-03 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-04 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-05 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-06 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-07 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-08 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-09 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-10 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-11 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-12 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-13 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-14 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-15 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-16 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-17 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-18 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-19 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-20 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-21 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-22 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-23 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-24 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-25 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-26 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-27 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-28 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-29 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-09-30 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-01 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-02 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-03 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-04 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-05 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-06 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-07 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-08 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-09 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-10 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-11 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-12 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-13 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-14 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-15 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-16 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-17 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-18 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-19 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-20 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-21 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-22 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-23 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-24 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-25 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-26 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-27 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-28 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-29 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-30 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-10-31 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-11-01 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-11-02 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-11-03 | $0.61 | $73,000,000 | 1 / 1 |
| 2026-11-04 | $0.61 | $73,000,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.